Drug
tunlametinib
tunlametinib is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_2
2
50%
Ph phase_3
1
25%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 22 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
recruiting4100%
Recent Activity
4 active trials
Showing 4 of 4
recruitingphase_4
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
NCT07445022
recruitingphase_2
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
NCT07170293
recruitingphase_2
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
NCT06970353
recruitingphase_3
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106
Clinical Trials (4)
Showing 4 of 4 trials
NCT07445022Phase 4
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
NCT07170293Phase 2
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
NCT06970353Phase 2
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
NCT06008106Phase 3
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4